Familial hypercholesterolemia (FH) is characterized by an autosomal dominantly inherited deficiency of LDL-receptor expression on the cell surface, leading to excess plasma LDL-cholesterol and severe premature atherosclerosis. In patients with heterozygous FH, a major therapeutic objective of conventional drug therapy is to stimulate maximally the residual cellular capacity to produce LDL-receptors via inhibition of endogenous cholesterol synthesis. In contrast, LDL-immunoapheresis aims at reducing the plasma LDL-cholesterol level by extracorporeal elimination of LDL particles. The present study investigates whether LDL-immunoapheresis applied in addition to conventional drug therapy is able to further stimulate residual LDL-receptor expression capacity in patients with heterozygous FH via the withdrawal of external cholesterol supply, thereby exerting a second accessory lipid lowering effect.
Methods
LDL-receptor expression-calculated by transforming mean fluorescence intensities into numbers of antibody binding sites per cell (S/C) was determined flow-cytometrically on peripheral blood monocytes before and after LDL-apheresis. For a comparison with the maximum obtainable receptor expression capacity, in vitro stimulation experiments under completely LDL deficient conditions were performed.
Results
Prior to LDL-apheresis, LDL-receptor density was comparable in patients (N=7; 2014 ± 359 S/C) and controls (N=10; 1782 ± 252 S/C). Under in vitro conditions LDL-receptor expression of controls exceeded that of patients with FH by 1.6 times. Immediately after apheresis, LDL-receptor expression significantly increased to almost the same level as obtained by in vitro stimulation (3640 ± 423 S/C and 3632 ± 572 S/C). The LDL-receptor expression in FH subsequent to LDL-apheresis exhibited two patterns of kinetics [Type 1: maximal receptor stimulation (288 ± 70%; P<0.07) already during apheresis; Type 2: highest receptor density 24 hours after treatment (149 ± 11%; P<0.01)].
Conclusions
These results demonstrate that despite drug therapy, LDL-apheresis significantly stimulates the residual LDL-receptor expression in FH via the reduction of available extracellular cholesterol resulting in delayed reappearance of hypercholesterolemia in between treatments.
PitasRE, FrieraA, McGuireJ, DejagerS.Further characterization of the acethyl LDL (scavenger) receptor expressed by rabbit smooth muscle cells and fibroblasts. Arterioscler Thromb1992;12(11):1235–44.
7.
KroonAA, van AstenWNJC, StalenhoefAFH. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med1996;125:945–54.
8.
KroonAA, AengevaerenWRW, van der WerfT, UijenGJH, ReiberJHC, BruschkeAVG, StalenhoefAFM. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation1996;93:1826–35.
9.
RichterWO, JacobBG, RitterMM, SühlerK, VierneiselK, SchwandtP.Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism1993;42:888–94.
WattsGF, BurkeV.Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol1996;7:341–55.
12.
SacksFM, PfefferMA, LemuelAM, RouleauJL, RutherfordJD, ColeTG, BrownL, WarnicaJW, ArnoldJMO, WunCC, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med1996;335:1001–9.
13.
JansenM, GabrielH, BanyaiS, PidlichJ, WeidingerF, HörlWH, DerflerK.Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient. Wien Klin Wochenschr1996;108(14):425–31.
14.
JohannessonM, JönssonB, KjekshusJ, OlssonAG, PedersenTR, WedelH.Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med1997;336(5):332–6.
15.
GordonBR, SaalSD. Current status of low density lipoproteinapheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol1996;7(6):381–4.
16.
TatamiR, InoueN, ItohH, KishinoB, KogaN, NakashimaY, NishideT, OkamuraK, SaitoY, TeramotoT, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis1992;95:1–13.
17.
ThompsonGR, MaherVMG, MatthewsS, KitanoY, NeuwirthC, ShorttMB, DaviesG, ReesA, MirA, PrescottRJ, et al. Familial hypercholesterolaemia regression study: a randomized trial of low-density-lipoprotein apheresis. Lancet1995;345:811–6.
18.
SwobodaK, DerflerK, KoppensteinerR, LangerM, PambergerP, EhringerH, DrumlW, WidhalmK.Extracorporeal lipid elimination for treatment of gestational hyperlipidemic pancreatitis. Gastroenterology1993;104:1527–31.
19.
SchmitzG, BrüningT, KovacsE, BarlageS.Fluorescence flow cytometry of human leukocytes in the detection of LDL receptor defects in the differential diagnosis of hypercholesterolemia. Arteriosclerosis and Thrombosis1993;13:1053–65.
20.
RudlingM, AngelinB.Stimulation of rat hepatic low density lipoprotein receptors by glucagon: evidence of a novel regulatory mechanism in vivo. J Clin Invest1993;91:2796–805.
21.
BeisiegelU, SchneiderWJ, GoldsteinJL, AndersonRGW, BrownMS. Monoclonal antibodies to the low density lipoprotein receptor as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia. J Biol Chem1981;256:11923–31.
22.
DerflerK, SwobodaK, HirschlMM, Gottsauner-WolfM, StegerG, Sunder-PlassmannG, WidhalmK.Comparison of plasma separation and immunospecific LDL-elimination in severe hypercholesterolemia. Int J Artif Organs1992;15:307–8.
23.
DerflerK.Long-term low-density lipoprotein immunoapheresis in renal disease. In: KeaneWF, HörlWH, KasiskeBL, eds. Lipids and the kidney. Vol. 120. Basel, Switzerland: Karger, 1997:105–19.
24.
Du MoulinA.LDL immunapheresis technique. Basel, Switzerland: Karger, 1990:170–4.
25.
BrownMS, GoldsteinJL. A receptor-mediated pathway for cholesterol homeostasis. Science1986;232:34–47.
26.
SüdhofTC, GoldsteinJL, BrownMS, RussellDW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science1985;228:815–22.
27.
BeisiegelU, WeberW, IhrkeG, HerzJ, StanleyKK. The LDL-receptor-related protein, LRP, is an apolipoprotein E binding protein. Nature1989;341:162–4.
28.
LiscumL, FaustJR. Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts. J Biol Chem1997;262:17002–8.
29.
BrownMS, GoldsteinJL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell1975;6:307.
30.
FranceschiniG, LovatiMR, ManzoniC, MichelagnoliS, PazzucconiF, GianfranceschiG, VecchioG, SirtoriCR. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis1995;114:61–71.
31.
MalleE, OettlK, SattlerW, HoeflerG, KostnerGM. Cholesterol biosynthesis in dermal fibroblasts from patients with metabolic disorders of peroxisomal origin. Eur J Clin Invest1995;25:59–67.
32.
RavehD, IsraeliA, ArnonR, EisenbergS.Effects of lovastatin on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins. Atherosclerosis1990;82:19–26.
33.
RoachPD, HoskingJ, CliftonPM, BaisR, KusenicB, CoyleP, WightMB, ThomasDW, NestelPJ. The effects of hypercholesterolaemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells. Atherosclerosis1993;103:245–54.
34.
QinW, InfanteJ, WangS-R, InfanteR.Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Biochim Biophys Acta1992;1127:57–66.
35.
GaddiA, ArcaM, CiarrocchiA, FazioS, D'AlòG, TiozzoR, DescovichGC, CalandraS.Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprtein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts. Metabolism1991;40(10):1074–8.
36.
ReihnerE, RudlingM, StahlbergD, BerglundL, EwerthS, BjörkheimI, EinarssonK, AngelinB.Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med1991;323:224–8.
37.
SteinEA. Drug and alternative therapies for hyperlipidemia. Atherosclerosis1994;108(Suppl):105–16.
38.
VegaGL, GrundySM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia. J Intern Med1991;230:341–9.
39.
SchoonjansK, WatanabeM, SuzukiH, MahfoudiA, KreyG, WahliW, GrimaldiP, StaelsB, YamamotoT, AuwerxJ.Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem1995;270:19269–76.
PfohlM, NaoumovaRP, KlassC, KniselW, JakoberB, RislerT, ThompsonGR. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res1994;35:1946–55.
HobbsHH, RussellDW, BrownMS, GoldsteinJL. The LDL receptor locus and familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet1990;24:133–70.
44.
DavisCG, GoldsteinJL, SüdhofTC, AndersonRGW, RussellDW, BrownMS. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature1987;326:760–5.
45.
HobbsHH, BrownMS, GoldsteinJL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat1992;1:445–66.
46.
LeitersdorfE, TobinEJ, DavignonJ, HobbsHH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest1990;85:1014–23.
47.
LehrmanMA, SchneiderWJ, BrownMS, DavisCG, ElhammerA, RussellDW, GoldsteinJL. The Lebanese allele at the LDL receptor locus: nonsense mutation produces truncated receptors that is retained in endoplasmic reticulum. J Biol Chem1987;262:401–10.
48.
BrownMS, AndersonRGW, GoldsteinJL. Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell1983;32:663–7.
49.
BasuSK, GoldsteinJL, AndersonRGW, BrownMS. Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts. Cell1991;24:493–502.
50.
VuorioAF, OjalaJP, SarnaS, TurtolaH, TikkanenMJ, KontulaK.Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and Pvull polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med1995;237:43–8.
